TTFields and chemo for metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a wearable device (TTFields) combined with a specific chemotherapy (mFOLFIRINOX) for people whose pancreatic cancer has spread to the liver and other organs. The device sends gentle electrical fields to disrupt cancer cell growth, and the chemo attacks cancer cells throughout the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread to other parts of your body (stage 4).
- You have at least one tumor in your liver that can be biopsied.
- You are healthy enough to be up and about (performance status 0 or 1).
- Your doctor plans to treat you with a chemotherapy called mFOLFIRINOX.
- You or a caregiver can use a wearable device that delivers electrical fields to the tumor area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.